Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
Eyes Have It in AbbVie Deal With Regenxbio
06:26pm, Monday, 13'th Sep 2021
To expand its footprint in eye care, AbbVie Inc.( ABBV , Financial) has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-are
Why Regenxbio Stock Is Way Up Today
02:40pm, Monday, 13'th Sep 2021
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration.
Why Regenxbio Shares Are Trading Higher Today
10:57am, Monday, 13'th Sep 2021
Regenxbio Inc (NASDAQ: RGNX) is trading significantly higher Monday after the company, and AbbVie Inc (NYSE: ABBV), announced an eye care collaboration. The companies will develop and commercialize RG
Here's why Regenxbio shares are up close to 30% on Monday morning
10:55am, Monday, 13'th Sep 2021
Regenxbio Inc (NASDAQ: RGNX) jumped about 30% in the stock market on Monday morning as it announced a partnership with the biopharmaceutical giant AbbVie Inc (NYSE: ABBV). “In collaboration with REG
AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration
08:39am, Monday, 13'th Sep 2021
AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age-related macular degeneration (wet AMD), d
AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billion
08:25am, Monday, 13'th Sep 2021
Shares of AbbVie Inc. ABBV, -0.55% were up 0.8% in premarket trading on Monday after the drug maker announced a potential billion-dollar deal to develop and commercialize Regenxbio Inc.'s RGNX, -1.66%
Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors
07:05am, Tuesday, 07'th Sep 2021
ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- Renowned gene therapy pioneer and biotechnology executive bring extensive R&D leadership and financial and operational expertise to the Board REGENXBIO
REGENXBIO Inc. (RGNX) CEO Ken Mills on Q2 2021 Results - Earnings Call Transcript
11:31pm, Monday, 09'th Aug 2021
REGENXBIO Inc. (RGNX) CEO Ken Mills on Q2 2021 Results - Earnings Call Transcript
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
04:05pm, Monday, 09'th Aug 2021
ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II tria
REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021 Financial Results and Recent Operational Highlights
04:05pm, Monday, 02'nd Aug 2021
ROCKVILLE, Md., Aug. 2, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, August 9, 2021, at 4:30 p.m.
Regenxbio: Suprachoroidal Data May Impress
09:24am, Tuesday, 06'th Jul 2021
Regenxbio (RGNX) has an internal gene therapy pipeline and also earns licensing revenue from partners using their IP.
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Wednesday, 09'th Jun 2021
ROCKVILLE, Md., June 9, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following June investor conferences, which will each be held in a virtual meeting
Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years
02:40pm, Friday, 14'th May 2021
Regenxbio Inc (NASDAQ: RGNX) has announced a safety update and additional positive interim data from its ongoing Phase 1/2 trial of RGX-121 to treat patients up to 5 years old diagnosed with Mucop
ROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events Biomarkers and measures of neurodev
Regenxbio: An Overlooked Gene Therapy Innovator
06:14am, Friday, 14'th May 2021
A powerful biotech company can undergo strong fundamentals development and yet its stock doesn't appreciate much at all.
